Corautus Enters Manufacturing Agreement With Boehringer Ingelheim

Corautus Genetics and Boehringer Ingelheim Austria GmbH announced that they have entered into a long term manufacturing agreement to produce VEGF-2 (Vascular Endothelial Growth Factor 2) plasmid DNA for a Phase III trial and future commercial use for the treatment of cardiovascular disease (severe angina) and other indications.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=239973&categoryid=21)